Viewing Study NCT05239533

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:48 AM
Ignite Modification Date: 2026-04-22 @ 2:54 AM
Study NCT ID: NCT05239533
Status: RECRUITING
Last Update Posted: 2025-05-18
First Post: 2022-02-07
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
Sponsor: Memorial Sloan Kettering Cancer Center
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Clear Cell Renal Cell Carcinoma View
None Kidney Cancer View
None Advanced Renal Cell Carcinoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Nivolumab View
None 177Lu-girentuximab View
None Clear Cell Renal Cell Carcinoma View
None Kidney Cancer View
None Advanced Renal Cell Carcinoma View
None Memorial Sloan Kettering Cancer Center View
None 21-328 View